drugset
drugset / Trial / NCT05616728

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

NCT05616728 ↗

Phase 2 Completed 231 enrolled Enanta Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.

Timeline

Start
2022-11-10
Primary completion
2023-02-08
Completion
2023-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP-235 Unknown 200 mg Oral
Subject EDP-235 Unknown 400 mg Oral

Indications

COVID-19